Fredriksson T, Pettersson U
Dermatologica. 1978;157(4):238-44. doi: 10.1159/000250839.
Ro 10-9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Doses of 25 mg b.i.d., 25 mg t.i.d. and 50 mg b.i.d. were administered orally to 27 patients suffering from severe chronic generalized psoriasis. The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions. At doses of 25 mg t.i.d. or 50 mg b.i.d. Ro 10--9359 proved to be an extremely potent antipsoriatic drug. A more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. This good effect lasted about 5 weeks after treatment. Side effects were frequent, but mostly mild and completely reversible after termination of treatment.
Ro 10-9359是一种维甲酸衍生物，因其在动物实验中显示出比维甲酸更好的耐受性而被选作研究对象。对27例重度慢性泛发性银屑病患者口服给药，剂量分别为每日两次25毫克、每日三次25毫克和每日两次50毫克。临床疗效通过一个新的指标——基于银屑病皮损严重程度和面积的银屑病面积和严重程度指数（PASI）进行评估。在每日三次25毫克或每日两次50毫克的剂量下，Ro 10-9359被证明是一种极其有效的抗银屑病药物。治疗4至8周后，20例患者中有10例的银屑病皮损减少了90%以上。这种良好效果在治疗后持续约5周。副作用很常见，但大多轻微，在治疗终止后完全可逆。
